Evaluation of HIV/AIDS clinical care quality: The case of a referral hospital in North West Ethiopia

International Journal for Quality in Health Care

Volumn 21, Issue 5, 2009, Pages 356-362

  Alemayehu, Yibeltal Kiflie ^a   Bushen, Oluma Yoseph ^b   Muluneh, Ayalew Tegegn ^a  

^a JIMMA UNIVERSITY   (Ethiopia)

^b TULANE UNIVERSITY   (United States)

Author keywords

Quality improvement; Quality indicators; Quality measurement

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ETHIOPIA; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH PERSONNEL ATTITUDE; HOSPITAL CARE; HOSPITAL LABORATORY; HUMAN IMMUNODEFICIENCY VIRUS; MEDICAL CARE; MEDICAL STAFF; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE ALLOCATION;

ADOLESCENT; ANTI-HIV AGENTS; ANTIBIOTIC PROPHYLAXIS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; ETHIOPIA; FEMALE; GUIDELINE ADHERENCE; HIV INFECTIONS; HUMANS; INFANT; MALE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; QUALITY OF HEALTH CARE; STAVUDINE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; YOUNG ADULT; ZIDOVUDINE;

EID: 70349630566     PISSN: 13534505     EISSN: 14643677     Source Type: Journal    
DOI: 10.1093/intqhc/mzp030     Document Type: Article

References (32)

1. FMOH/FHAPCO. AIDS in Ethiopia: Sixth report. http://www.etharc.org/ aidsineth/publications/AIDSinEth6th_en.pdf (12 December 2006, date last accessed).
2. World Health Organization. Progress on Global Access to HIV Antiretroviral Therapy: A Report on '3 by 5' and Beyond. Geneva: World Health Organization, 2006.
3. UNAIDS. 2006 Report on the global AIDS epidemic. 2006
4. Federal HIV/AIDS Prevention and Control Office/Federal Ministry of Health. Guidelines for management of opportunistic infections and antiretroviral treatment in adolescents and adults in Ethiopia. http://www.etharc.org/arvinfo/ethOIArtif.uideline_2007.pdf (11 November 2007, date last accessed).
5. Federal MOH/Federal HAPCO. Guideline for cotrimoxazole prophylaxis in HIV/AIDS care and treatment. http://www.etharc.org/arvinfo/ cotromoxizoleguide.pdf (12 May 2006, date last accessed).
6. Palella FJ, Jr, oria-Knoll M, Chmiel JS et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003;138:620-6.
7. Mocroft A, Lundgren JD. Starting highly active antiretroviral therapy: why, when and response to HAART. J Antimicrob Chemother 2004;54 10-3.
8. Liu C, Weber K, Robison E et al. Assessing the effect of HAART on change in quality of life among HIV-infected women. AIDS Res Ther 2006;3:6.
9. FHAPCO. Monthly ART update as of September 10, 2007. 2007
10. Wilson IB, Landon BE, Marsden PV et al. Correlations among measures of quality in HIV care in the United States: Cross sectional study. Br Med J 2007;335:1085.
11. McGlynn EA, Asch SM, Adams J et al. The quality of health care delivered to adults in the United States. i N Engl J Med 2003;348 2635-45.
12. Jencks SF, Cuerdon T, Burwen DR et al. Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels. J Am Med Assoc 2000;284:1670-6.
13. Schuster MA, McGlynn EA, Brook RH. How good is the quality of health care in the United States? 1998. Milbank Q 2005;83:843-95.
14. Donabedian A. An Introducation to Quality Assurance in Health Care New York: Oxford University Press, 2003.
15. Tadios Y, Davey G. Antiretroviral treatment adherence and its correlates in Addis Ababa, Ethiopia. Ethiop Med J 2006;44:237-44.
16. Donabedian A. Evaluating the quality of medical care. 1966. Milbank Q 2005;83:691-729.
17. New York State Department of Health AIDS Institute, Johns Hopkins University. HIV clinical resource: Adult and adolescent indicators. http://www.hivguidelines.org/Content.aspx?pageID=36 (15 July 2006, date last accessed), 2006.
18. McNaghten AD, Hanson DL, Jones JL et al. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS 1999;13:1687-95.
19. Grimwade K, Sturm AW, Nunn AJ et al. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005;19:163-8.
20. Walker AS, Mulenga V, Ford D et al. The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis 2007;44:1361-7.
21. Anglaret X, Chene G, Attia A et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: A randomised trial. Cotrimo-CI Study Group. Lancet 1999;353:1463-8.
22. World Health Organization, UNAIDS. Antibiotic recommendation for African HIV patients. 2000. 2007
23. Enrico Girardia. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000;14:1985-91.
24. Phillips AN, Staszewski S, Weber R et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. J Am Med Assoc 2001;286:2560-7.
25. World Health Organization. Scaling up antiretroviral therapy in resource limitted settings: Treatment guidelines for a public health approach. http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf, 2007.
26. Mannheimer SB, Matts J, Telzak E et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 2005;17:10-22.
27. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
28. Hogg RS, Heath K, Bangsberg D et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002;16:1051-8.
29. Bangsberg DR, Perry S, Charlebois ED et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-3.
30. Garcia de Olalla P, Knobel H, Carmona A et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002;30:105-10.
31. Hogg RS, Yip B, Chan KJ et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. J Am Med Assoc 2001;286:2568-77.
32. Peabody JW, Luck J, Glassman P et al. Comparison of vignettes, standardized patients, and chart abstraction: A prospective validation study of 3 methods for measuring quality. JAMA 2000;283 1715-22.